Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).

Erba HP, Sayar H, Juckett M, Lahn M, Andre V, Callies S, Schmidt S, Kadam S, Brandt JT, Van Bockstaele D, Andreeff M.

Invest New Drugs. 2013 Aug;31(4):1023-34. doi: 10.1007/s10637-013-9935-x. Epub 2013 Feb 10.

2.

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.

Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M.

Cancer. 2012 Jan 15;118(2):418-27. doi: 10.1002/cncr.26292. Epub 2011 Jun 29.

3.

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors.

Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S, Tamura T.

Cancer Chemother Pharmacol. 2011 Aug;68(2):505-11. doi: 10.1007/s00280-010-1506-7. Epub 2010 Nov 16.

PMID:
21079959
4.

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M.

J Clin Oncol. 2009 Oct 1;27(28):4741-6. doi: 10.1200/JCO.2009.21.8172. Epub 2009 Aug 3.

5.

Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.

Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH.

J Clin Oncol. 1997 Aug;15(8):2780-5.

PMID:
9256119
6.

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.

Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S.

Am J Hematol. 2013 Nov;88(11):961-6. doi: 10.1002/ajh.23544. Epub 2013 Sep 9.

7.

[Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia].

Qian SX, Li JY, Wu HX, Lu H, Qiu HX, Chen LJ, Lu RN, Xu W, Sheng RL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):209-13. Chinese.

PMID:
19236781
8.

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.

Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA.

Pediatr Blood Cancer. 2014 Oct;61(10):1754-60. doi: 10.1002/pbc.25117. Epub 2014 Jun 29.

9.

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.

Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ.

Cancer Chemother Pharmacol. 2003 Jan;51(1):87-90. Epub 2002 Nov 13.

PMID:
12497211
10.

Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias.

Carella AM, Pungolino E, Piatti G, Gaozza E, Nati S, Spriano M, Giordano D, D'Amico T, Damasio E.

Eur J Haematol. 1989 Oct;43(4):309-13.

PMID:
2583257
11.

XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.

Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M.

Apoptosis. 2011 Jan;16(1):67-74. doi: 10.1007/s10495-010-0545-1.

12.

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.

Ye XN, Zhou XP, Wei JY, Xu GX, Li Y, Mao LP, Huang J, Ren YL, Mei C, Wang JH, Lou YJ, Ma LY, Yu WJ, Ye L, Xie LL, Luo YW, Hu C, Niu LM, Dou MH, Jin J, Tong HY.

Leuk Lymphoma. 2016;57(6):1311-8. doi: 10.3109/10428194.2015.1091931. Epub 2015 Oct 13.

PMID:
26372888
13.
14.

The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.

Lee SR, Yang DH, Ahn JS, Kim YK, Lee JJ, Choi YJ, Shin HJ, Chung JS, Cho YY, Chae YS, Kim JG, Sohn SK, Kim HJ.

J Korean Med Sci. 2009 Jun;24(3):498-503. doi: 10.3346/jkms.2009.24.3.498. Epub 2009 Jun 15.

15.

A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.

Bassan R, Lerede T, Buelli M, Borleri G, Bellavita P, Rambaldi A, Barbui T.

Haematologica. 1998 May;83(5):422-7.

16.

High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.

Low M, Lee D, Coutsouvelis J, Patil S, Opat S, Walker P, Schwarer A, Salem H, Avery S, Spencer A, Wei A.

Intern Med J. 2013 Mar;43(3):294-7. doi: 10.1111/j.1445-5994.2012.02868.x. Review.

PMID:
22757980
17.

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM.

J Clin Oncol. 2003 Mar 15;21(6):1050-6. Erratum in: J Clin Oncol. 2004 Apr 1;22(7):1351. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.

PMID:
12637470
19.

Clofarabine combinations as acute myeloid leukemia salvage therapy.

Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM.

Cancer. 2008 Oct 15;113(8):2090-6. doi: 10.1002/cncr.23816.

20.

Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.

Harousseau JL, Reiffers J, Hurteloup P, Milpied N, Guy H, Rigal-Huguet F, Facon T, Dufour P, Ifrah N.

J Clin Oncol. 1989 Jan;7(1):45-9.

PMID:
2642539

Supplemental Content

Support Center